What is Degarelix?
Degarelix is a GnRH antagonist used in prostate-cancer hormone therapy. PRONOUNCE examined cardiovascular events against leuprolide but ended before its planned enrollment.
Biological role or research focus
Prostate-cancer hormone therapy and cardiovascular outcomes.
Early termination and fewer events than planned leave cardiovascular superiority unresolved. A nonsignificant comparison is not proof of equivalence.
- Class / identity
- GnRH receptor antagonist
- Research focus
- Prostate-cancer hormone therapy and cardiovascular outcomes
- Featured evidence
- Human randomized trial
- Source check
- October 4, 2026
Quick answers
- Is Degarelix FDA approved?
- Yes. Firmagon (NDA 022201, approved December 2008) for advanced prostate cancer. Source ↗
- Is Degarelix safe?
- Approved hormone-blocking drug for advanced prostate cancer; injection-site reactions and hot flashes are common, with heart rhythm (QT) and allergy risks. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Degarelix banned in sport?
- It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| PRONOUNCE (2021) | Human randomized trial | 545 patients with prostate cancer and atherosclerotic cardiovascular disease; planned enrollment was 900. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2021
PRONOUNCE
Did cardiovascular events differ versus leuprolide?
- Population / model
- 545 patients with prostate cancer and atherosclerotic cardiovascular disease; planned enrollment was 900.
- Study design
- Randomized open-label comparison with leuprolide over 12 months; adjudicated cardiovascular endpoints; stopped early.
- Main finding
- Major cardiovascular events occurred in 5.5% versus 4.1%: hazard ratio 1.28 (95% CI 0.59–2.79; P=0.53).
- Limits & context
- Early termination and fewer events than planned leave cardiovascular superiority unresolved. A nonsignificant comparison is not proof of equivalence.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
65 registered studies name Degarelix as an intervention among the 100 most recently updated of 170 search results; 25 are recruiting or under way, 1 has not started recruiting yet, 28 completed and 11 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 65 listed studies.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. ↗
BJU international · 2008 Dec · Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial
ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer. ↗
European urology · 2023 Jun · Randomized Controlled Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't
Degarelix. ↗
· 2012 · Review
Degarelix. ↗
Drugs · 2009 Oct 1 · Journal Article
Risks & interactions
Approved hormone-blocking drug for advanced prostate cancer; injection-site reactions and hot flashes are common, with heart rhythm (QT) and allergy risks.
Safety comes from FDA-approved labeling (Firmagon) based mainly on a one-year randomized trial against leuprolide in men with prostate cancer, plus postmarketing reports. No formal drug interaction studies were done.
Take extra care with: Heart or blood pressure problemsPregnancy or breastfeeding
From the FDA label lists below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.
Who should not use it
- People with a past severe allergic reaction to degarelix or any product component
Interactions
- Drugs that prolong the QT interval: androgen deprivation can also prolong QT, adding heart rhythm risk
Serious risks
- Severe allergic reactions, including anaphylaxis and angioedema
- QT prolongation (a heart rhythm change), especially with long QT syndrome, heart failure or electrolyte problems
- Fetal harm and pregnancy loss, based on animal studies
- Can alter results of hormone-related lab tests
Common side effects
- injection-site pain, redness or swelling
- hot flashes
- raised liver enzymes
Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Firmagon (degarelix) prescribing information ↗
What the featured evidence can tell us
Current medicine information should guide precautions and monitoring. PRONOUNCE does not establish that either approach has no cardiovascular risk.
Source: NCI · Degarelix ↗
Identity, route, and evidence limits
Early termination and fewer events than planned leave cardiovascular superiority unresolved. A nonsignificant comparison is not proof of equivalence.
Regulatory status
- U.S. FDA approval
- Approved
Firmagon (NDA 022201, approved December 2008) for advanced prostate cancer. source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source - World Anti-Doping Agency (2026)
- Not on the WADA Prohibited List
Not named. S2.2.1 covers GnRH agonist analogues; degarelix is a GnRH antagonist. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Medicine status & clinical context
NCI identifies degarelix, marketed as Firmagon, as FDA-approved for advanced prostate cancer. The PRONOUNCE study examines cardiovascular outcomes within that treatment setting; it does not establish a general longevity or cardiovascular-prevention indication.
NCI identifies degarelix as a prostate-cancer treatment. The featured trial addresses a narrower cardiovascular-safety comparison in people with established atherosclerotic cardiovascular disease.
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
This is a prescription medicine, available only with a prescription through a pharmacy. Versions sold online as "research" products are not the approved medicine, and the FDA has warned sellers of them, so PepsRadar does not list, compare or link them. See the official product information linked in References.
How Degarelix works
GnRH receptor antagonism suppresses the reproductive-hormone pathway through a different receptor approach from GnRH agonists. A mechanistic difference does not itself prove cardiovascular superiority.
Molecular structure
Questions worth asking
- Did PRONOUNCE prove better cardiovascular safety?
- What population, comparator, and route were actually studied?
- Early termination and fewer events than planned leave cardiovascular superiority unresolved. A nonsignificant comparison is not proof of equivalence.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Did PRONOUNCE prove better cardiovascular safety?
No. The trial stopped early and the event comparison was not statistically significant; the comparative question remained unresolved.
Does this page establish a supplier’s product quality?
No. A publication describes its own tested material. It does not verify a supplier listing, batch identity, purity, or clinical suitability.
Does the official medicine reference cover every use discussed online?
No. The reference covers defined products and clinical settings. Research outside those uses needs separate evidence and does not extend the medicine’s authorization.
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
